A steroidal antiviral agent

Abstract

The invention relates to a steroid antiviral agent, wherein a steroid compound has a structure as the formula I. The antiviral agent includes one or more of the compound as the formula I, or a stereoisomer, a geometric isomer, a tautomer, a solvate, a pre-drug or a pharmaceutically-acceptable salt of the compound I as effective components. The compound I has quite strong inhibition activity on respiratory syncytial virus (RSV) in paramyxoviridae, and can be used as an antiviral medicine or a lead compound of the antiviral medicine.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry and relates to a steroidal antiviral agent. In particular, it relates to a steroidal antiviral agent having extremely strong inhibitory activity against respiratory syncytial virus (RSV) of the family Paramyxoviridae. Background technique [0002] Respiratory syncytial virus (respiratory syncytial virus pneumonia, referred to as syncytial virus, RSV, also belongs to Paramyxoviridae), is an RNA virus, which belongs to Paramyxoviridae. RSV infection can cause pneumonia and a variety of lower respiratory diseases. Every year, at least 3 million infants and young children worldwide are hospitalized due to RSV virus infection, and at least 160,000 of them die. Therefore, RSV is also known as a child killer (Science, 2013, 342, 546 -547). Currently there is no clinically applicable vaccine, and ribavirin (ribavirin) is the only chemotherapeutic drug used clinically (J.Med.Chem.2008, 51, 875-896). I...

AI Technical Summary

Problems solved by technology

There is currently no clinically applicable vaccine, and ribavirin (ribavirin) is the only chemotherapeutic drug used clinically (J.Med.Chem.2008,51,875–896)

Images